Gustave Roussy uses SOPHiA DDM™ Platform to
empower confident, data-driven medicine in the fight against
cancer
BOSTON and ROLLE, Switzerland, Aug. 22,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company in the healthcare space and a
leader in data-driven medicine, today announced the expansion
of its relationship with Gustave Roussy, the leading cancer center
in Europe. With the expanded
relationship SOPHiA GENETICS will now further support Gustave
Roussy via the SOPHiA DDM™ Platform, which will provide expedited
analysis and insights of genomic profiles.
Gustave Roussy is considered among the top 3 specialized
hospitals in the world. The institute treats patients of all ages
and types of cancer and is an expert in the treatment of rare and
complex tumors. With a vision to expand the limits of knowledge and
offer patients personalized treatment, the institute began working
with SOPHiA GENETICS in 2017 and recently expanded its use of
SOPHiA GENETICS technology after a public tender. Gustave Roussy
will now utilize the SOPHiA DDM™ Platform for all relevant samples,
including those related to solid tumors, hematologic and hereditary
cancers.
"With the rapidly evolving field of clinical genomics, the
challenges of data analysis are now twofold – the ability to meet
the production quality requirements, which are becoming more and
more stringent with the IVDR regulations, and the ability to
innovate with the arrival of new genomic signatures and techniques.
The SOPHiA DDM™ Platform, a recognized solution in terms of quality
– ISO13485 and ISO27001 - and performance, was the optimal solution
for Gustave Roussy," said Etienne
Rouleau, Head of Genetics Unit at Gustave Roussy.
The development of treatment plans for patients with
cancer requires institutions to consider an enormous
amount of data, which is both time intensive and costly. The
expanded use of SOPHiA GENETICS by Gustave Roussy will allow the
institute to accelerate diagnostics, and thus the development of
cancer treatment plans via optimized workflows that aid clinicians
in more quickly drawing meaningful insights from medical data.
"SOPHiA GENETICS is uniquely positioned to facilitate the
analysis of clinical, biological, and genomics data to provide
real-world insights on tumor-driving mutations, variant analysis,
and assist in the acceleration of clinical trial performance," said
Philippe Menu, MD, Chief Medical Officer, SOPHiA GENETICS. "We are extremely proud to work
with Gustave Roussy to help more cancer patients obtain
personalized treatments through the most advanced technologies
available, expanding the availability of data-driven medicine."
Gustave Roussy has updated its Laboratory Information Management
System (LIMS) to create bi-directional communication between the
existing Gustave Roussy database and the SOPHiA DDM™ Platform. This
is expected to facilitate more efficient interpretation of data and
help Gustave Roussy advance the use of precision medicine, while
maintaining ownership over its variant databases and laboratory
systems.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native software company
in the healthcare space dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-native platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by a broad network of
hospital, laboratory, and biopharma institutions globally. For more
information, visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram. Where others
see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-expands-relationship-with-gustave-roussy-301906123.html
SOURCE SOPHiA GENETICS